The Use of PWI and DWI Measures in the Design of “Proof‐of‐Concept” Stroke Trials
- 1 April 2004
- journal article
- Published by Wiley in Journal of Neuroimaging
- Vol. 14 (2) , 123-132
- https://doi.org/10.1111/j.1552-6569.2004.tb00228.x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Tirilazad Mesylate in Acute Ischemic StrokeStroke, 2000
- Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trialThe Lancet, 2000
- Selfotel in Acute Ischemic StrokeStroke, 2000
- Intra-arterial Prourokinase for Acute Ischemic StrokeJAMA, 1999
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)Published by Elsevier ,1998
- Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke: A Randomized Controlled TrialJAMA, 1998
- Lubeluzole Treatment of Acute Ischemic StrokeStroke, 1997
- Streptokinase for Acute Ischemic Stroke With Relationship to Time of AdministrationJAMA, 1996
- Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric StrokeJAMA, 1995
- Characterization of the Cerebroprotective Efficacy of the Competitive NMDA Receptor Antagonist CGP40116 in a Rat Model of Focal Cerebral Ischemia: An in vivo Magnetic Resonance Imaging StudyJournal of Cerebral Blood Flow & Metabolism, 1993